CN Patent

CN116554042A — 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗

Assigned to CanSino Biologics Inc · Expires 2023-08-08 · 3y expired

What this patent protects

本发明提供了一种新型阳离子脂质和脂质纳米颗粒及核酸疫苗。本发明选择特定的阳离子脂质制备的脂质纳米颗粒mRNA疫苗，发现其较现有技术中的阳离子脂质制备的LNP具有更好的体外稳定性以及免疫原性。

USPTO Abstract

本发明提供了一种新型阳离子脂质和脂质纳米颗粒及核酸疫苗。本发明选择特定的阳离子脂质制备的脂质纳米颗粒mRNA疫苗，发现其较现有技术中的阳离子脂质制备的LNP具有更好的体外稳定性以及免疫原性。

Drugs covered by this patent

Patent Metadata

Patent number
CN116554042A
Jurisdiction
CN
Classification
—
Expires
2023-08-08
Drug substance claim
No
Drug product claim
No
Assignee
CanSino Biologics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.